Ilyang announces positive results for ilaprazole in phase 3 study

Ilyang Pharm announced on August 8 that it has completed a multinational Phase 3 clinical study for ilaprozole, a new proton pump inhibitor, in six South East Asian countries including Thailand, Malaysia and Singapore.

During the study, the efficacy and safety of ilaprozole 10 mg was superior to those of omperazole 20 mg in patients with Helicobacter Pylori infection, gastroesophageal reflux...